Home Applications 201023 Application 201023
Type NDA
Sponsor SANOFI AVENTIS US Application Products# Product, Drug, Ingredient table Product Drug Ingredient Form Strength Reference drug Reference standard 001 JEVTANA KIT CABAZITAXEL SOLUTION;INTRAVENOUS 60MG/1.5ML (40MG/ML) Yes Yes
Source provenance: Browse the complete Orange Book source catalog · source snapshot 44 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N201023-001 JEVTANA KIT CABAZITAXEL 60MG/1.5ML (40MG/ML) SOLUTION / INTRAVENOUS AP RLD, RS 2010-06-17
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 1 matching rows.
Application-product, TE code table Application-product TE code N201023-001 AP
Orange Book patents# Current patent rows page 1 of 1 · 10 matching rows.
Application-product, Patent, Expiration table Application-product Patent Expiration Use code Coverage / status Submission date N201023-001 7241907 2025-12-10 Drug substance N201023-001 7241907*PED 2026-06-10 Pediatric extension N201023-001 10583110 2030-10-27 U-2753 2020-03-17 N201023-001 10716777 2030-10-27 U-2856 2020-07-21 N201023-001 12453712 2030-10-27 U-4334 2025-11-28 N201023-001 8927592 2030-10-27 U-3200 2015-01-12 N201023-001 10583110*PED 2031-04-27 Pediatric extension N201023-001 10716777*PED 2031-04-27 Pediatric extension N201023-001 12453712*PED 2031-04-27 Pediatric extension N201023-001 8927592*PED 2031-04-27 Pediatric extension
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 2 of 2 · 44 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2022-10-28 04:53 UTC 2022-10 N201023-001 JEVTANA KIT 60MG/1.5ML (40MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2010-06-17 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N201023-001 JEVTANA KIT 60MG/1.5ML (40MG/ML) SOLUTION / INTRAVENOUS RLD, RS 2010-06-17 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N201023-001 JEVTANA KIT 60MG/1.5ML (40MG/ML) SOLUTION / INTRAVENOUS AP RLD, RS 2010-06-17 cb3db0bc1861…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N201023-001 JEVTANA KIT 60MG/1.5ML (40MG/ML) SOLUTION / INTRAVENOUS AP RLD, RS 2010-06-17 a50c72e98297…
Observed Orange Book normalized TE history# Observed Orange Book patent history# Patent history page 1 of 8 · 295 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-10-15 13:18:30 2026-09 N201023-001 7241907 2025-12-10 Drug substance c2088c7a36db…2026-10-15 13:18:30 2026-09 N201023-001 7241907*PED 2026-06-10 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N201023-001 10583110 2030-10-27 U-2753 2020-03-17 c2088c7a36db…2026-10-15 13:18:30 2026-09 N201023-001 10716777 2030-10-27 U-2856 2020-07-21 c2088c7a36db…2026-10-15 13:18:30 2026-09 N201023-001 12453712 2030-10-27 U-4334 2025-11-28 c2088c7a36db…2026-10-15 13:18:30 2026-09 N201023-001 8927592 2030-10-27 U-3200 2015-01-12 c2088c7a36db…2026-10-15 13:18:30 2026-09 N201023-001 10583110*PED 2031-04-27 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N201023-001 10716777*PED 2031-04-27 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N201023-001 12453712*PED 2031-04-27 Pediatric extension c2088c7a36db…2026-10-15 13:18:30 2026-09 N201023-001 8927592*PED 2031-04-27 Pediatric extension c2088c7a36db…2026-09-14 22:38:34 2026-08 N201023-001 7241907 2025-12-10 Drug substance 84e616aacf4f…2026-09-14 22:38:34 2026-08 N201023-001 7241907*PED 2026-06-10 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N201023-001 10583110 2030-10-27 U-2753 2020-03-17 84e616aacf4f…2026-09-14 22:38:34 2026-08 N201023-001 10716777 2030-10-27 U-2856 2020-07-21 84e616aacf4f…2026-09-14 22:38:34 2026-08 N201023-001 12453712 2030-10-27 U-4334 2025-11-28 84e616aacf4f…2026-09-14 22:38:34 2026-08 N201023-001 8927592 2030-10-27 U-3200 2015-01-12 84e616aacf4f…2026-09-14 22:38:34 2026-08 N201023-001 10583110*PED 2031-04-27 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N201023-001 10716777*PED 2031-04-27 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N201023-001 12453712*PED 2031-04-27 Pediatric extension 84e616aacf4f…2026-09-14 22:38:34 2026-08 N201023-001 8927592*PED 2031-04-27 Pediatric extension 84e616aacf4f…2026-08-18 06:07:40 2026-07 N201023-001 7241907 2025-12-10 Drug substance caaa826d4ba7…2026-08-18 06:07:40 2026-07 N201023-001 7241907*PED 2026-06-10 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N201023-001 10583110 2030-10-27 U-2753 2020-03-17 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N201023-001 10716777 2030-10-27 U-2856 2020-07-21 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N201023-001 12453712 2030-10-27 U-4334 2025-11-28 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N201023-001 8927592 2030-10-27 U-3200 2015-01-12 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N201023-001 10583110*PED 2031-04-27 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N201023-001 10716777*PED 2031-04-27 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N201023-001 12453712*PED 2031-04-27 Pediatric extension caaa826d4ba7…2026-08-18 06:07:40 2026-07 N201023-001 8927592*PED 2031-04-27 Pediatric extension caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N201023-001 7241907 2025-12-10 Drug substance 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N201023-001 7241907*PED 2026-06-10 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N201023-001 10583110 2030-10-27 U-2753 2020-03-17 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N201023-001 10716777 2030-10-27 U-2856 2020-07-21 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N201023-001 12453712 2030-10-27 U-4334 2025-11-28 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N201023-001 8927592 2030-10-27 U-3200 2015-01-12 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N201023-001 10583110*PED 2031-04-27 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N201023-001 10716777*PED 2031-04-27 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N201023-001 12453712*PED 2031-04-27 Pediatric extension 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N201023-001 8927592*PED 2031-04-27 Pediatric extension 011fe1cb6892…
Observed Orange Book exclusivity history# openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 1 matching rows.
Brand, Generic, Manufacturer table Brand Generic Manufacturer SPL set ID Effective date Available safety fields Join Jevtana CABAZITAXEL Sanofi-Aventis U.S. LLC de3d9c26-572b-4ea4-9b2d-dd58a2b3e8fa 2025-10-07 Boxed warning, Warnings, Adverse reactions Exact identifier application applno (NDA): 201023 application number: NDA201023 ndc (product): 0024-5824
Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
NDC Listings For This Application# NDC listings for this application page 1 of 1 · 5 matching rows.
NDC, Name, Nonproprietary name table NDC Name Nonproprietary name Labeler Marketing category Status 0024-5824 Jevtana cabazitaxel Sanofi-Aventis U.S. LLC NDA Current 0024-5824 Jevtana cabazitaxel Sanofi-Aventis U.S. LLC NDA Current 0024-5824 Jevtana cabazitaxel Sanofi-Aventis U.S. LLC NDA Current 0024-5824 Jevtana cabazitaxel Sanofi-Aventis U.S. LLC NDA Current 0024-5824 Jevtana cabazitaxel Sanofi-Aventis U.S. LLC NDA Current